4SCAR-T Therapy Post CD19-targeted Immunotherapy

Clinical trial NCT04430530 · RECRUITING

Trial details

NCT number: NCT04430530
Sponsor: Shenzhen Geno-Immune Medical Institute
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

CD19 Negative B-cell Malignancies

Start date: 2026-06-01
Primary completion: 2029-12-31
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.